Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Once-Daily RGT001-075 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (COMO-1)

NCT06867718 is registered in ClinicalTrials.gov with Regor Pharmaceuticals Inc. as lead sponsor.

NCT NCT06867718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06867718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Once-Daily RGT001-075 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities (COMO-1)
Lead sponsor
Regor Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 24, 2025
Completion date
November 6, 2025
Enrollment
267 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

obesity or overweight